STRO Sutro Biopharma Inc

$-0.33 (-4.25%)

STRO Stock Analysis Overview

What this means: InvestorsObserver gives Sutro Biopharma Inc (STRO) an overall rank of 33, which is below average. Sutro Biopharma Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 33 means that 67% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full STRO report

Sutro Biopharma Inc (STRO) Analyst Forecast

Next 12 months ➝Current Price$7.4452-week High$12.7552-week Low$6.00MEAN$19.00+155.38%HIGH$22.00+195.70%LOW$16.00+115.05%
  • Last Price$7.44
  • Previous Close$7.77
  • Change $-0.33
  • Open$7.93
  • Volume302,035
  • Avg. Volume (100-day)104,020
  • Market Capitalization$267M
  • Days Range $7.33 - $7.93
  • 52-week Range $6.00 - $12.75
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-2.64
  • Earnings Date08/12/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta2.243
  • PEG Ratio
  • Volatility0.69
  • Average True Range0.07
Sutro Biopharma Inc is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.